Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Common Equity: 2016-2024

Historic Common Equity for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $222.4 million.

  • Tg Therapeutics' Common Equity rose 216.00% to $607.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $607.2 million, marking a year-over-year increase of 216.00%. This contributed to the annual value of $222.4 million for FY2024, which is 38.54% up from last year.
  • Per Tg Therapeutics' latest filing, its Common Equity stood at $222.4 million for FY2024, which was up 38.54% from $160.5 million recorded in FY2023.
  • Tg Therapeutics' 5-year Common Equity high stood at $519.4 million for FY2020, and its period low was $58.6 million during FY2022.
  • Its 3-year average for Common Equity is $147.2 million, with a median of $160.5 million in 2023.
  • As far as peak fluctuations go, Tg Therapeutics' Common Equity spiked by 1,244.94% in 2020, and later slumped by 75.30% in 2022.
  • Over the past 5 years, Tg Therapeutics' Common Equity (Yearly) stood at $519.4 million in 2020, then crashed by 54.34% to $237.2 million in 2021, then plummeted by 75.30% to $58.6 million in 2022, then surged by 173.95% to $160.5 million in 2023, then spiked by 38.54% to $222.4 million in 2024.